Health Care·Pharmaceuticals·$153.6B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.62 | N/A | -2.64% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $1.62 | N/A | -2.64% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management remains focused on innovation and long-term growth. They acknowledged current market pressures but emphasized their commitment to advancing their portfolio.
Management highlighted ongoing efforts in research and development.
They expressed confidence in future product pipelines despite current challenges.
Pfizer's earnings report shows a slight miss on EPS, which may raise concerns among investors. However, the stock reacted positively, increasing by 1.97%. This could indicate that investors are optimistic about the company's long-term prospects despite the EPS miss.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
ENTERPRISE PRODS PAR
May 2, 2022